Oct 07, 2022 15:00 JST
Source: Olympus
|
|
Olympus EU-ME3 Ultrasound Processor, Delivers Higher Resolution Images for Endoscopic Ultrasound
~ Supporting More Accurate Diagnosis and Treatment of Pancreaticobiliary and Lung Disease ~
- EU-ME3 at United European Gastroenterology Week (UEG Week 2022) October 8 to 11 -
TOKYO / HAMBURG, Oct 07, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of EU-ME3, a new Endoscopic Ultrasound Processor*, which addresses the needs of healthcare professionals for high-quality clear images when conducting the endoscopic ultrasound procedure. EU-ME3 will be launched in Europe, the Middle East, Africa, parts of Asia, and Oceania within this fiscal year.
 | Olympus announces the global launch of the EVIS EUS / EU-ME3 Endoscopic Ultrasound Center. [Image: Olympus Corp] |
Olympus, a pioneer in endoscopic ultrasound (EUS) technology, aims to leverage its expertise to enhance the care pathway in gastrointestinal and respiratory disease management. The technology is used for endoscopic ultrasonography, imaging to support the diagnosis of lesions in the pancreas, the bile ducts, or lesions that are located deep inside the body and are not visible with gastrointestinal endoscopes. In addition, it enables the detailed examination of pancreatitis, pancreatic cancer, and the diagnosis of cancer invasion in the stomach and the esophagus. Endoscopic ultrasound also plays a key role in facilitating the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for early, minimally invasive diagnosis and lung cancer staging.
"It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers. With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients," said Hironobu Kawano, Head of Endoscopic Solutions Division at Olympus.
- Advancing the dimensions of endosonography
With the needs of healthcare professionals and patient outcomes at its core, EU-ME3 is tailored to improve a variety of procedures.
- Enhanced visualization and usability
EU-ME3 provides outstanding image quality and functionality. The image quality has been substantially enhanced compared to the prior generation model (EU-ME2), providing enhanced visualization, therefore supporting a more reliable diagnosis and treatment.
Shear Wave Quantification, a newly equipped feature for EU-ME3, also contributes to accurate diagnosis by providing quantitative information on the stiffness of tumor and inflamed lesions, which is an important factor when diagnosing the degree of pancreatitis and malignancy of pancreatic cancer during endoscopic ultrasonography.
- Focus on procedure, with tailored technology
The Endoscopic ultrasound procedure typically utilizes a variety of observation modes dependent on procedure type or clinical area. Subsequently, in addition to the basic observation mode, EU-ME3 offers multiple software options for individual clinical needs, aiming to stay flexible in the selection of functions and tailor EU-ME3 depending on specialty.
Smart and customizable user settings make it easy to fulfil needs for multiple specialties and personal requirements. The backlit keyboard includes a simple, easy-to-use large touch panel and trackpad, designed to support better operability and easier cleaning.
With EU-ME3, the aim is to provide seamless workflow integration for healthcare professionals while advancing the dimensions of Endosonography for better overall patient outcome.
About Olympus
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world's first gastrocamera in 1950, Olympus' Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, digital and integrated customer solutions, as well as solutions for infection prevention. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
Media Contacts Nao Tsukamoto - Global-Public_Relations@olympus.com Jessica Lee - Jessica.yy.lee@fleishman.com
* Registered name: EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME3. EU-ME3 is manufactured by Olympus Medical Systems Corporation. * Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLY] https://www.olympus-global.com
Source: Olympus Sectors: BioTech, Healthcare & Pharm, MedTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
 Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential Jul 30, 2025 22:41 JST
|  Production, Sales and Export Results for June, 2025 Jul 30, 2025 18:24 JST
|  Sales, Production, and Export Results for the First Half of 2025 Jul 30, 2025 18:06 JST
|  Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB Jul 30, 2025 11:00 JST
|  Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide Jul 29, 2025 20:00 JST
|  Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum" Jul 29, 2025 14:30 JST
|  LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Jul 29, 2025 09:01 JST
|  Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics Jul 25, 2025 16:00 JST
|  Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment Jul 25, 2025 13:31 JST
|  Fujitsu and Nagoya University develop simulation tech to combat transportation gaps Jul 24, 2025 12:30 JST
|  Honda Reveals Details of its Support of the World Athletics Championships Tokyo 25 Jul 24, 2025 12:03 JST
|  Prototype divertor outer vertical target for the ITER fusion experimental reactor is completed and the sample has passed the ITER Organization's certification test Jul 23, 2025 13:10 JST
|  Sharp Exhibits at the 2nd SPEXA - International Space Business Expo
Jul 23, 2025 10:30 JST
|  Launch of Beova(R) Tablets in Thailand for Overactive Bladder Jul 23, 2025 10:07 JST
|  Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support Jul 23, 2025 10:00 JST
|  Mitsubishi Motors to Terminate Its Joint Venture Partnership with Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Jul 22, 2025 17:00 JST
|  Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 Jul 22, 2025 11:56 JST
|  Anime Tokyo Station TV Anime "SPYxFAMILY" Special Exhibition Jul 22, 2025 11:00 JST
|  ShrimpTech JIRCAS and IMT Engineering Announce Strategic Collaboration to Advance Land-Based Aquaculture Jul 22, 2025 09:00 JST
|  Honda Koraidon First Showrun during Suzuka 8 Hours
Jul 18, 2025 11:06 JST
|
More Latest Release >>
|